Evaluation of the Safety and Performance of Magneto PE Kit

Inclusion Criteria: * Clinical signs, symptoms and presentation consistent with acute PE * PE symptom duration ≤ 14 days * CTA evidence of PE * RV/LV ratio ≥ 0.9 * Heart rate \<130 BPM prior to procedure * Subject medically eligible for interventional procedure * Age ≥ 18 and \<75 years * Consent process is completed Exclusion Criteria: * Thrombolytic use within 14 days * Known bleeding diathesis or coagulation disorder * Any contraindication to systemic therapeutic doses of heparin or other anticoagulants * Hemodynamic collapse at presentation * Decompensated heart failure * Presence of Extra-Corporeal Membrane Oxygenation. * Major trauma ISS\> 15 within 14 days * Cardiovascular or pulmonary surgery within last 7 days * FiO2 requirement \> 40% or \> 6 LPM to keep oxygen saturation \> 90% * Hematocrit \< 28% * Platelets \< 100,000/µL * Serum creatinine \> 1.8 mg/dL * INR\>2 * Left bundle branch block * PAP \> 70 mmHg m * Imaging evidence suggests subject is not appropriate for mechanical thrombectomy * Presence of intracardiac lead in right ventricle or atrium. * Pacemaker or Implantable Cardioverter Defibrillator * Presence of intracardiac thrombus * Anaphylactic reaction to radiographic contrast agents that cannot be pre-treated * Known right- to-left shunt, * Known left ventricular ejection fraction ≤ 30% * History of severe chronic pulmonary arterial hypertension * History of underlying lung disease with oxygen dependence * History of chest irradiation * History of Heparin Induced Thrombocytopenia (HIT) * Female who is pregnant or nursing * Current participation in another investigational drug or device treatment study * Life expectancy of \< 90 days as determined by the investigator * Subjects who are intubated